- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01230346
Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer
Intervention to Promote Uptake of Cancer Risk Counseling for Underserved Latinas
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To conduct a randomized trial of a culturally-informed pre-genetic cancer risk assessment (GCRA) telephone intervention.
II. To evaluate the effect of the pre-GCRA intervention versus a time and attention control versus standard scheduling procedure alone (usual care) on levels of anxiety, perceived personal control and cancer genetics knowledge.
III. To explore patients' experiences with the pre-GCRA intervention through post-intervention telephone interviews.
SECONDARY OBJECTIVES:
I. To explore patients' perceived barriers to GCRA through no-show telephone interviews.
OUTLINE:
Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive a culturally-informed adapted motivational interviewing telephone call.
ARM II: Patients participate in a controlled condition comprising a health habits intervention group.
ARM III: Patients receive usual care comprising a standard scheduling phone call and proceed with normal GCRA process. All patients are mailed standard new patient packets containing questionnaires on demographics and personal health history, and a family history form. All patients then undergo genetic cancer risk assessment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Medical Center
-
Los Angeles, California, United States, 90033
- University of Southern California-Keck School of Medicine
-
Sylmar, California, United States, 91342
- Olive View-UCLA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Individuals who have a personal history of hereditary breast or ovarian cancer; a subset of 60 women without a personal history of hereditary or ovarian cancer will be included in an exploratory subset analysis
- Meet NCCN criteria for consideration of genetic testing for hereditary breast cancer
- Willing to sign consent
- Pregnant women and women of child-bearing potential are eligible for participation in this study
- Women who report themselves to be of Latino or Hispanic ethnic background (defined as Spanish, Mexican, Central or South American, Cuban, Puerto Rican, Dominican, or other Hispanic origin)
- Women who are under- or uninsured and come from low-income communities
- Ability to understand English or Spanish
Exclusion Criteria:
- Previous participation in GCRA
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Arm I
Patients receive a culturally-informed adapted motivational interviewing telephone call.
|
Ancillary studies
Ancillary studies
Telephone intervention
Other Names:
Telephone intervention
Other Names:
|
|
Experimental: Arm II
Patients participate in a controlled condition comprising a health habits intervention group.
|
Ancillary studies
Ancillary studies
Telephone intervention
Other Names:
|
|
Active Comparator: Arm III
Patients receive usual care comprising a standard scheduling phone call and proceed with normal GCRA process.
|
Ancillary studies
Ancillary studies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Effect of pre-GCRA intervention versus a time and attention control versus standard scheduling procedure alone (usual) on levels of anxiety, perceived personal control and cancer genetic knowledge
Time Frame: One week after genetic cancer risk assessment (GCRA)
|
Tested using 3 x 3 repeated measures analysis of covariance (ANCOVA)s in which the within subjects variables are anxiety or perceived control, the between groups variable is group membership, and covariates include fatalism and other appropriate moderators.
|
One week after genetic cancer risk assessment (GCRA)
|
|
Experiences with the pre-GCRA intervention through post-intervention telephone interviews
Time Frame: One week after genetic cancer risk assessment (GCRA)
|
One week after genetic cancer risk assessment (GCRA)
|
|
|
Conduct a randomized controlled trial of a culturally-informed pre-GCRA telephone intervention utilizing AMI techniques
Time Frame: One week after genetic cancer risk assessment (GCRA)
|
Will use a multivariate ANCOVA (MANCOVA) to test for group differences among all five preparedness scores, with step-down F ratios of each individual score, using fatalism and other moderators as covariates, as appropriate.
|
One week after genetic cancer risk assessment (GCRA)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Perceived barriers to GCRA through no-show telephone interviews
Time Frame: One week after genetic cancer risk assessment (GCRA)
|
One week after genetic cancer risk assessment (GCRA)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bita Nehoray, City of Hope Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Disease
- Neoplasms, Glandular and Epithelial
- Skin Diseases
- Breast Diseases
- Syndrome
- Carcinoma
- Breast Neoplasms
- Investigative Techniques
- Health Services
- Health Care Facilities Workforce and Services
- Child Health Services
- Community Health Services
- Preventive Health Services
- Behavioral Disciplines and Activities
- Mental Health Services
- Methods
- Early Intervention, Educational
- Counseling
Other Study ID Numbers
- 08237
- NCI-2010-01998
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BRCA1 Syndrome
-
Memorial Sloan Kettering Cancer CenterMemorial Health University Medical CenterCompleted
-
Memorial Sloan Kettering Cancer CenterCureBRCA FoundationRecruitingBRCA1/2 | Geneitic TestingUnited States
-
University of PennsylvaniaCompleted
-
National Cancer Institute (NCI)CompletedBRCA1 Gene | BRCA2 GeneUnited States
-
Azienda Ospedaliera Universitaria Policlinico Paolo...Unknown
-
Abramson Cancer Center at Penn MedicineInovio PharmaceuticalsActive, not recruiting
-
Memorial Sloan Kettering Cancer CenterUniversity of Pennsylvania; University of California, Los Angeles; Dana-Farber... and other collaboratorsActive, not recruiting
-
Rabin Medical CenterUnknownBRCA1 Gene Mutation | BRCA2 Gene MutationIsrael
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingBRCA1 Mutation | BRCA2 MutationItaly
-
Duke UniversityRecruitingBRCA1 Mutation | BRCA2 MutationUnited States
Clinical Trials on questionnaire administration
-
Fondazione Don Carlo Gnocchi OnlusCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Istanbul Aydın UniversityCompleted
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Université Catholique de LouvainRecruiting
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingCOVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingEndometrial Carcinoma | Malignant Uterine Neoplasm | Uterine Corpus Cancer | Uterine Corpus SarcomaUnited States
-
Ohio State University Comprehensive Cancer CenterNational Center for Complementary and Integrative Health (NCCIH)CompletedBreast Cancer | Prostate CancerUnited States